Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Retained Earnings (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Retained Earnings for 5 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 697.89% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 697.89% year-over-year, with the annual reading at $1.1 million for FY2025, 697.89% up from the prior year.
  • Retained Earnings hit $1.1 million in Q4 2025 for Krystal Biotech, up from $1.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $1.5 million in Q3 2024 to a low of -$359.3 million in Q2 2023.
  • Historically, Retained Earnings has averaged -$129.3 million across 5 years, with a median of -$129.9 million in 2021.
  • Biggest five-year swings in Retained Earnings: crashed 1042280.95% in 2022 and later skyrocketed 697.89% in 2025.
  • Year by year, Retained Earnings stood at -$140.8 million in 2021, then crashed by 99.43% to -$280.8 million in 2022, then soared by 100.23% to $638000.0 in 2023, then plummeted by 129.78% to -$190000.0 in 2024, then surged by 697.89% to $1.1 million in 2025.
  • Business Quant data shows Retained Earnings for KRYS at $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $1.2 million in Q2 2025.